Pharmaceuticals
Latest news, explainers and analysis on Pharmaceuticals. Tracking 22 stories on Arth Vani.
Connected in the graph
Latest on Pharmaceuticals
Sun Pharma to Cut US Drug Prices Amid Affordability Drive; Analysts See Limited Impact
Sun Pharmaceutical Industries has agreed to lower its drug prices in the United States, aligning them with other developed nations as part of an initiative to enhance healthcare affordability for low-income Americans. Despite the company's substantial US revenue, financial analysts believe this move will have only a minimal impact on Sun Pharma's overall financial performance.
Evonik Invests C$150 Million in Canada for Advanced Drug Delivery Systems
Evonik is investing over C$150 million (approximately €93 million) to expand its lipid-based drug delivery manufacturing capabilities with a new facility in Vancouver, Canada. This expansion will boost the production of lipid nanoparticles (LNPs), which are critical components for developing advanced medicines and vaccines for clinical trials.
Moderna Shares Plunge 7% Amid Profit Booking After 392% Year-to-Date Surge
Shares of pharmaceutical giant Moderna fell 7% as traders booked profits after the stock had surged an impressive 392% year-to-date. Other major pharma companies, including BioNTech and Merck, also experienced declines, reflecting broader investor sentiment in the sector.
IPOBreakingSymbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion
Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.
Druckenmiller Bets on Rhythm Pharma for Rare Obesity Untouched by Eli Lilly, Novo Nordisk
Billionaire investor Stanley Druckenmiller is reportedly investing in Rhythm Pharmaceuticals, a company focused on treating rare genetic forms of obesity. This move stands apart from the broader market trend, as Rhythm's treatments target conditions not addressed by popular weight-loss drugs from pharmaceutical giants like Eli Lilly and Novo Nordisk. Druckenmiller's strategy highlights a focus on specialized, unmet medical needs within the burgeoning obesity treatment sector.
AbbVie Stock Performance Decouples from Broader Market Trends
Pharmaceutical giant AbbVie is showing a unique trading pattern where its stock price movements are increasingly driven by internal company developments rather than broader market volatility. This shift highlights the importance of company-specific catalysts like drug approvals and patent cycles over macroeconomic factors for global healthcare investors.
Govt to Ban Drugmakers for Mislabeling and Fraudulent Approvals Under New Rules
The Union Health Ministry has amended the Drugs Rules, 1945, to strictly bar pharmaceutical companies from selling products approved through false information. The new regulations empower authorities to debar manufacturers and distributors to ensure medicine safety for Indian consumers.
Takeda's Qdenga Dengue Vaccine Approved in India, Commercial Launch Expected 2027
Takeda Pharmaceutical's new dengue vaccine, Qdenga, has received approval in India. The vaccine is slated for commercial launch in early 2027, initially targeting the private market for individuals before potential government procurement.
AstraZeneca, Bristol Myers Squibb Reportedly Eyeing $400 Billion Merger Deal
UK pharmaceutical giant AstraZeneca and its US rival Bristol Myers Squibb are reportedly in discussions for a massive $400 billion merger. If realized, this megadeal would create one of the world's largest drugmakers, significantly reshaping the global pharmaceutical landscape.
BreakingSun Pharma Initiates Recall of Multiple Eye Drop Brands Across India Over Contamination
Sun Pharmaceutical Industries Ltd. has commenced a product withdrawal for several of its eye drop brands in India, citing contamination concerns. This recall affects a range of commonly used ophthalmic solutions, including Depopred, Brinolar, Brinzotim, Lotepred, Nepalact, and Toba-F products.
ChrysCapital Takes Controlling Stake in Novartis India; New CEO Appointed
Indian private equity firm ChrysCapital has acquired a controlling stake in Novartis India Limited, marking its first majority-controlled investment in the country's pharmaceutical sector. As part of this significant development, a new Chief Executive Officer has been appointed to lead Novartis India.
Panmure Sees Further Growth for Hikma After Recent Stock Rally
Analyst firm Panmure believes that pharmaceutical company Hikma's stock recovery story still has more potential for growth, even after its recent rally. This outlook suggests a continued positive trajectory for the global company's shares.
Indian Biotech Sector Booms as Startup Count Hits 2,400; PE Investments Double
India's pharmaceutical and biotech landscape is witnessing a massive shift with private equity investments doubling to $731 million. A new report highlights that the number of biotech startups has surged to 2,400, signaling a robust pipeline for new drug development.
Dr. Reddy's Semaglutide Supply Faces Delay, No Recall Risk
Dr. Reddy's Laboratories has announced a delay in the supply of its Semaglutide, a key diabetes and weight-loss drug. The company clarified that this is a supply chain issue and not related to any quality concerns or a product recall.
Sun Pharma Shares Register Weekly Growth, Signalling Positive Investor Mood
Sun Pharmaceutical Industries Ltd. shares have shown positive movement over the past week, indicating a favourable sentiment among investors. This weekly growth is a key point of interest for those tracking the pharmaceutical sector and Sun Pharma's market performance. It suggests increased buying interest for the company's stock.
Sun Pharma Shares Slip Below Key Technical Support; Analysts Monitor Short-Term Weakness
India's largest pharmaceutical company, Sun Pharma, has witnessed a technical breakdown as its share price dropped below a critical support level. This movement suggests a potential period of volatility and short-term pressure for retail investors holding the stock.
Shift to Pharma and Metals: Expert Advice as Global Tensions Ease
Market veteran Sudip Bandyopadhyay suggests investors pivot toward defensive sectors like pharmaceuticals and healthcare. As geopolitical risks in West Asia soften, focus is shifting to sectors with clear earnings visibility and industrial growth potential.
Dabur Under Lens After US FDA Issues Import Alert on Silvassa Plant Products
Shares of Dabur India are in the spotlight following a US FDA import alert on drugs produced at its Silvassa facility. The regulatory action stems from data integrity concerns, though the company maintains that the impact on overall business is minimal.
Sun Pharma Stock Dips: Is This a Buying Opportunity or Sector Warning?
India's largest pharmaceutical company, Sun Pharma, has witnessed a notable decline in its share price over the past month. Investors are now weighing whether this dip represents a value-buying chance or signals a broader slowdown in the pharma sector.
Sun Pharma Shares See Short-Term Dip: What Retail Investors Need to Know
India's pharmaceutical giant, Sun Pharmaceutical Industries, has experienced a performance cooling over the last month. This dip is significant for retail investors as it directly impacts the valuation of major blue-chip portfolios and sectoral mutual funds.
Kotak Mutual Fund Invests ₹612 Crore in Emcure Pharma; PE Firm BC Investments Exits
Private equity firm BC Investments IV has sold its stake in Emcure Pharmaceuticals to Kotak Mutual Fund for ₹612 crore. This major transaction highlights growing institutional confidence in Emcure's growth potential across key medical segments.
Big Win for Ajanta Pharma as Mutual Fund Giants Buy Shares Worth ₹1,024 Crore
Promoters of Ajanta Pharma have offloaded shares worth over ₹1,024 crore in a massive block deal. Leading institutional investors, including Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund, have stepped in to pick up the stake, signaling strong long-term confidence in the drugmaker.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.